S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Mereo BioPharma Group plc (MPH.L) Share Forecast, Price & News

GBX 26.50
-0.50 (-1.85%)
(As of 12/17/2020)
Today's Range
50-Day Range
52-Week Range
49,264 shs
Average Volume
333,975 shs
Market Capitalization
£89.76 million
P/E Ratio
Dividend Yield
Price Target

Mereo BioPharma Group plc (MPH.L) MarketRank™ Forecast

Analyst Rating
Short Interest
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.33 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive MPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter.

Mereo BioPharma Group plc (MPH.L) logo

About Mereo BioPharma Group plc (MPH.L) (LON:MPH) Stock

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

MPH Stock News Headlines

Why Mereo BioPharma Shares Are Jumping Today
Is MREO A Good Stock To Buy Now?
BioNTech SE: Biopharma Leaders Unite to Stand with Science
See More Headlines

Industry, Sector and Symbol

Year Founded

Company Calendar

Last Earnings


Pretax Margin


Sales & Book Value

Annual Sales
Cash Flow
GBX 17.12 per share
Book Value
GBX 7.20 per share


Free Float
Market Cap
£89.76 million
Not Optionable

Mereo BioPharma Group plc (MPH.L) Frequently Asked Questions

How has Mereo BioPharma Group plc (MPH.L)'s stock price performed in 2022?

Mereo BioPharma Group plc (MPH.L)'s stock was trading at GBX 26.50 on January 1st, 2022. Since then, MPH shares have increased by 0.0% and is now trading at GBX 26.50.
View the best growth stocks for 2022 here

How were Mereo BioPharma Group plc (MPH.L)'s earnings last quarter?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) posted its quarterly earnings results on Tuesday, September, 29th. The company reported ($105.00) earnings per share for the quarter.
View Mereo BioPharma Group plc (MPH.L)'s earnings history

Who are Mereo BioPharma Group plc (MPH.L)'s key executives?

Mereo BioPharma Group plc (MPH.L)'s management team includes the following people:
  • Dr. Denise Scots-Knight, Co-Founder, CEO & Exec. Director (Age 61, Pay $751.37k)
  • Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 51, Pay $545.68k)
  • Dr. Alastair MacKinnon, Co-Founder & Chief Medical Officer (Age 50, Pay $540.12k)
  • Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 63, Pay $512.99k)
  • Mr. Michael Stephen Wyzga MBA, Interim CFO & Exec. Director (Age 65, Pay $27.59k)
  • Ms. Alexandra Hughes-Wilson, Head of Patient Access & Commercial Planning (Age 49, Pay $265.93k)
  • Ms. Jill Henrich, US Site Head & Sr. VP of Regulatory Affairs (Age 57, Pay $286.93k)
  • Dr. John A. Lewicki, Chief Scientific Officer (Age 68)
  • Dr. Fiona Bor, Head of Intellectual Property
  • Mr. Ian Hodgson, Head of Clinical Operations

What other stocks do shareholders of Mereo BioPharma Group plc (MPH.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group plc (MPH.L) investors own include Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Inovio Pharmaceuticals (INO), Micron Technology (MU), Tesla (TSLA), Amgen (AMGN), ARMOUR Residential REIT (ARR), Arena Pharmaceuticals (ARNA) and Ardelyx (ARDX).

What is Mereo BioPharma Group plc (MPH.L)'s stock symbol?

Mereo BioPharma Group plc (MPH.L) trades on the London Stock Exchange (LON) under the ticker symbol "MPH."

How do I buy shares of Mereo BioPharma Group plc (MPH.L)?

Shares of MPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Mereo BioPharma Group plc (MPH.L)'s stock price today?

One share of MPH stock can currently be purchased for approximately GBX 26.50.

How much money does Mereo BioPharma Group plc (MPH.L) make?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) has a market capitalization of £89.76 million.

How many employees does Mereo BioPharma Group plc (MPH.L) have?

Mereo BioPharma Group plc (MPH.L) employs 50 workers across the globe.

How can I contact Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L)'s mailing address is 1 Cavendish Place, LONDON, W1G 0QF, United Kingdom. The official website for Mereo BioPharma Group plc (MPH.L) is mereobiopharma.com. The company can be reached via phone at 44 33 3023 7300.

This page (LON:MPH) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.